HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. (Q53434514)

14 May 2018

title

HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. (English)

1 reference

14 May 2018

0 references

1 reference

2

1 reference

14 May 2018

Yoon-Seok Chang

8

1 reference

14 May 2018

author name string

Jae-Woo Jung

1

1 reference

14 May 2018

Yon-Su Kim

3

1 reference

14 May 2018

Kwon Wook Joo

4

1 reference

14 May 2018

Kyung Wha Lee

5

1 reference

14 May 2018

Sae-Hoon Kim

6

1 reference

14 May 2018

Heung-Woo Park

7

1 reference

14 May 2018

Sang-Heon Cho

9

1 reference

14 May 2018

Kyung-Up Min

10

1 reference

14 May 2018

Hye-Ryun Kang

11

1 reference

14 May 2018

language of work or name

English

0 references

publication date

10 March 2011

1 reference

14 May 2018

Nephrology Dialysis Transplantation

published in

1 reference

14 May 2018

volume

26

1 reference

14 May 2018

page(s)

3567-3572

1 reference

14 May 2018

issue

11

1 reference

14 May 2018

Severe adverse cutaneous reactions to drugs

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

New insights into the epidemiology of gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

HLA-B locus in Caucasian patients with carbamazepine hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

Human leukocyte antigens and drug hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

Pathogenesis of ankylosing spondylitis: current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

Urate oxidase (rasburicase) for treatment of severe tophaceous gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR060

21 January 2018

Identifiers

DOI

10.1093/NDT/GFR060

1 reference

14 May 2018

PubMed ID

21393610

1 reference

14 May 2018